Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $319.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lifted by Morgan Stanley from $314.00 to $319.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley‘s price objective suggests a potential upside of 37.57% from the stock’s previous close.

Several other equities analysts have also recently weighed in on JAZZ. Royal Bank Of Canada lifted their price target on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research report on Tuesday. Weiss Ratings cut Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, October 28th. Robert W. Baird raised their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $292.95.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded up $17.45 during trading on Tuesday, hitting $231.88. The company’s stock had a trading volume of 647,883 shares, compared to its average volume of 929,876. The company has a market cap of $15.05 billion, a PE ratio of 16.02, a P/E/G ratio of 0.41 and a beta of 0.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The business has a fifty day moving average of $231.16 and a 200-day moving average of $216.50. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping analysts’ consensus estimates of ($4.05) by $0.17. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.13 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This represents a 53.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total transaction of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares in the company, valued at approximately $33,425,541.60. This trade represents a 1.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 94,121 shares of company stock worth $23,337,922 in the last 90 days. 4.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Triumph Capital Management increased its holdings in Jazz Pharmaceuticals by 2.0% during the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock valued at $626,000 after purchasing an additional 52 shares during the period. XML Financial LLC grew its position in shares of Jazz Pharmaceuticals by 1.1% in the 3rd quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company’s stock worth $1,519,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. grew its position in shares of Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after buying an additional 73 shares during the last quarter. Root Financial Partners LLC grew its position in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after buying an additional 89 shares during the last quarter. Finally, Evergreen Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals by 4.2% during the third quarter. Evergreen Capital Management LLC now owns 2,250 shares of the specialty pharmaceutical company’s stock valued at $521,000 after buying an additional 90 shares during the period. 89.14% of the stock is owned by institutional investors.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised 2026 guidance: Jazz now expects approximately $4.8 billion-$4.9 billion in full-year revenue, above the roughly $4.7 billion analyst consensus. The company cited sustained commercial execution and expects the Ziihera launch to support growth. Jazz Pharmaceuticals 2026 revenue guidance
• Positive Sentiment: Q3 beat expectations: Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year and ahead of the $1.21 billion consensus. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Xywav revenue grew 12%, with 425 net patient additions during the quarter. Jazz Pharmaceuticals third-quarter 2026 results
• Positive Sentiment: Analyst optimism: Royal Bank of Canada raised its price target to $305 and retained an “outperform” rating, while Barclays increased its target to $275 and maintained an “overweight” rating. The revisions reinforce expectations for additional upside. Royal Bank of Canada Jazz Pharmaceuticals rating
• Neutral Sentiment: Jazz launched Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma and says the product could eventually reach $3 billion-$5 billion in peak sales. The company also completed its Actio acquisition, adding the ABS-1230 epilepsy candidate.
• Neutral Sentiment: Jazz will present Phase 3 ACTION trial and other neuro-oncology data at the Society for Neuro-Oncology meeting later this month, creating a potential near-term catalyst but with clinical-outcome uncertainty. Jazz Pharmaceuticals neuro-oncology research
• Negative Sentiment: The quarterly loss compares with $8.13 in earnings per share a year earlier, while some commentary highlighted slowing growth and charges related to the Actio acquisition. These factors could limit enthusiasm despite the revenue beat.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.